NFKB1 and neoplasm: This observation does not exclude the possibility of NF-κB inhibition by sulindac and/or PDTC in case of activation of NF-κB in some circumstances, e.g. following standard chemotherapy (30) or in tumor cells with high constitutive expression of NF-κB.